iRhythm Technologies Inc
Fechado
SetorSaúde
110.8 -1.33
Visão Geral
Variação de preço das ações
24h
Mín
110.69
Máximo
112.34
Rendimento | 14M -381K |
|---|---|
Vendas | 25M 224M |
EPS | 0.58 |
Margem de lucro | -0.17 |
Funcionários | 2,400 |
EBITDA | 6.5M 2.9M |
Próximos Ganhos | 29 de out. de 2026 |
|---|
Capitalização de Mercado | -40M 4.1B |
|---|---|
Abertura anterior | 112.13 |
Fecho anterior | 110.8 |
Sentimento de Notícias
By Acuity
50%
50%
126 / 339 Ranking em Healthcare
iRhythm Technologies Inc Gráfico
O desempenho passado não é um indicador confiável de resultados futuros.
Notícias Relacionadas
Comparação entre Pares
Variação de preço
iRhythm Technologies Inc Previsão
Sentimento
By Acuity
126 / 339 Ranking em Saúde
Sentimento de Notícias
Neutral
Volatilidade
Abaixo da média
Volume de Notícias (RCV)
Abaixo da média
Informação Financeira
Custos administrativos e de venda
Custos Operacionais
Lucro antes de imposto
Vendas
Custo das vendas
Lucro bruto sobre vendas
Despesa com juros da dívida
EBITDA
Resultado Operacional
$
Sobre iRhythm Technologies Inc
iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.